Mapreg

Executive Summary

Mapreg is a French biotechnology company founded in 2007, focused on developing first-in-class small molecule 'neuroplastogens' for central nervous system (CNS) disorders. Based on foundational discoveries in neurosteroids by its renowned scientific founders, the company aims to heal the brain by re-driving neuroplasticity from within neurons. Currently in the pre-clinical stage, Mapreg has not disclosed any specific pipeline candidates, but its proprietary platform targets key CNS conditions such as depression, anxiety, and neurodegenerative diseases. The company operates privately in Paris and has not reported any fundraising or valuation data. Mapreg's approach is innovative, as it seeks to harness endogenous neurosteroid pathways to promote neuroplasticity, potentially offering differentiated efficacy and safety profiles compared to existing therapies. However, the company remains at an early stage with no publicly available preclinical or clinical data. Given the high unmet need in CNS disorders and the scientific foundation of its technology, Mapreg holds promise but faces significant development risks. The next 12-18 months will be critical for Mapreg to advance its lead candidate toward IND-enabling studies and to attract potential partnerships or funding.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Neuroplastogen Candidate15% success
• Q4 2025Preclinical Proof-of-Concept Data Release40% success
• H2 2025Strategic Partnership or Series A Financing30% success